Therapeutic Utility of Palmitoylethanolamide in the Treatment of Neuropathic Pain Associated with Various Pathological Conditions: a Case Series

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2012 Nov 21

PMID 23166447

Citations 37

Authors

Jan M Keppel Hesselink

Thecla Am Hekker

Affiliations

Soon will be listed here.

Abstract

Palmitoylethanolamide (PEA), an endogenous fatty acid amide, has been demonstrated to bind to a receptor in the cell nucleus - the peroxisome proliferator-activated receptor - and performs a great variety of biological functions related to chronic and neuropathic pain and inflammation, as has been demonstrated in clinical trials. These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia, and vaginal pains. Probably due to the fact that PEA is an endogenous modulator as well as a compound in food, such as eggs and milk, no serious side effects have been reported, nor have drug-drug interactions. This article presents a case series describing the application and potential efficacy and safety of PEA in the treatment of various syndromes associated with chronic pain that is poorly responsive to standard therapies.

Citing Articles

A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review.

Varrassi G, Rekatsina M, Leoni M, Cascella M, Finco G, Sardo S Pain Ther. 2024; 14(1):81-101.

PMID: 39630391 PMC: 11751209. DOI: 10.1007/s40122-024-00685-4.

Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis.

Kumar A, Tatarian J, Shakhnovich V, Chevalier R, Sudman M, Lovell D Metabolites. 2024; 14(9).

PMID: 39330506 PMC: 11434325. DOI: 10.3390/metabo14090499.

Palmitoylethanolamide as a Supplement: The Importance of Dose-Dependent Effects for Improving Nervous Tissue Health in an In Vitro Model.

Galla R, Mule S, Ferrari S, Grigolon C, Molinari C, Uberti F Int J Mol Sci. 2024; 25(16).

PMID: 39201765 PMC: 11354262. DOI: 10.3390/ijms25169079.

Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials.

DAngelo M, Steardo Jr L Int J Mol Sci. 2024; 25(7).

PMID: 38612415 PMC: 11011314. DOI: 10.3390/ijms25073603.

Micronized Palmitoylethanolamide, Hempseed Oil, and Maritime Pine Bark Dry Extract (Pelvipea) for Pelvic Pain: An In Vitro Study for Urothelial Inflammation Treatment.

Tafuri A, Panunzio A, De Mitri R, Benetti F, Gaio E, Pagliarulo V Cells. 2023; 12(4).

PMID: 36831284 PMC: 9953806. DOI: 10.3390/cells12040616.

References

Cerrato S, Brazis P, Della Valle M, Miolo A, Puigdemont A . Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet Immunol Immunopathol. 2009; 133(1):9-15. DOI: 10.1016/j.vetimm.2009.06.011. View

Naderi N, Majidi M, Mousavi Z, Tusi S, Mansouri Z, Khodagholi F . The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats. Neurochem Res. 2011; 37(4):778-85. DOI: 10.1007/s11064-011-0672-2. View

Loverme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G . Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther. 2006; 319(3):1051-61. DOI: 10.1124/jpet.106.111385. View

Ruessmann H . Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. J Diabetes Complications. 2008; 23(3):174-7. DOI: 10.1016/j.jdiacomp.2008.02.002. View

Marini I, Bartolucci M, Bortolotti F, Gatto M, Bonetti G . Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012; 26(2):99-104. View

Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M . Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun. 2011; 25(6):1099-112. DOI: 10.1016/j.bbi.2011.02.006. View

Liebregts R, Kopsky D, Keppel Hesselink J . Topical amitriptyline in post-traumatic neuropathic pain. J Pain Symptom Manage. 2011; 41(4):e6-7. DOI: 10.1016/j.jpainsymman.2011.01.003. View

Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C . Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2012; 10(8):916-20. DOI: 10.2174/187152711799219307. View

Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O . Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain. Pharmacology. 2006; 76(4):157-62. DOI: 10.1159/000091228. View

10.

Ziegler D, Ametov A, Barinov A, Dyck P, Gurieva I, Low P . Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006; 29(11):2365-70. DOI: 10.2337/dc06-1216. View

11.

Appendino G, Ligresti A, Minassi A, Cascio M, Allara M, Taglialatela-Scafati O . Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009; 52(9):3001-9. DOI: 10.1021/jm900130m. View

12.

De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli M, de Novellis V . Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain. 2011; 7:3. PMC: 3034677. DOI: 10.1186/1744-8069-7-3. View

13.

Thaler A, Gupta A, Cohen S . Cannabinoids for pain management. Adv Psychosom Med. 2011; 30:125-138. DOI: 10.1159/000324070. View

14.

Kopsky D, Keppel Hesselink J . Multimodal Stepped Care Approach Involving Topical Analgesics for Severe Intractable Neuropathic Pain in CRPS Type 1: A Case Report. Case Rep Med. 2011; 2011:319750. PMC: 3199095. DOI: 10.1155/2011/319750. View

15.

Vorobeychik Y, Gordin V, Mao J, Chen L . Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs. 2011; 25(12):1023-34. DOI: 10.2165/11596280-000000000-00000. View

16.

Finnerup N, Sindrup S, Jensen T . The evidence for pharmacological treatment of neuropathic pain. Pain. 2010; 150(3):573-581. DOI: 10.1016/j.pain.2010.06.019. View

17.

Dworkin R, OConnor A, Audette J, Baron R, Gourlay G, Haanpaa M . Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010; 85(3 Suppl):S3-14. PMC: 2844007. DOI: 10.4065/mcp.2009.0649. View

18.

Jaggi A, Singh N . Therapeutic targets for the management of peripheral nerve injury-induced neuropathic pain. CNS Neurol Disord Drug Targets. 2011; 10(5):589-609. DOI: 10.2174/187152711796235041. View

19.

Phan N, Siepmann D, Gralow I, Stander S . Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges. 2009; 8(2):88-91. DOI: 10.1111/j.1610-0387.2009.07213.x. View

20.

Loria F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangomez M . Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci. 2008; 28(4):633-41. DOI: 10.1111/j.1460-9568.2008.06377.x. View